# Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020

> Briefs, arguments, decisions, and more.

URL: https://www.frixlaw.com/law-library/documents/fr%3A2026-19498

## Record

- **Collection:** Federal Register
- **Document type:** Notice
- **Published:** September 23, 2026
- **Citation:** 91 FR 60360

## Text

DEPARTMENT OF COMMERCE
Bureau of Industry and Security
[Docket No. 260918-0006]
RIN 0694-XC154
Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020

AGENCY:

Bureau of Industry and Security, Office of Strategic Industries and Economic Security, U.S. Department of Commerce.

ACTION:

Notice.

SUMMARY:

This notice defines the pharmaceutical products and lists the jurisdictions that are eligible to receive an
ad valorem
tariff rate of zero pursuant to Presidential Proclamation 11020 of April 2, 2026, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,” (Proclamation 11020). These pharmaceutical products include drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; and animal health. Proclamation 11020 states that such products and associated ingredients receive the Section 232 zero tariff rate if they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement or if they meet an urgent U.S. health need. This notice also includes procedures for the public to submit information for the Department of Commerce's (Commerce) approval to determine if imports of the pharmaceutical products and associated ingredients meet an urgent U.S. health need. This notice also issues five technical corrections to Annex I and one technical correction to Annex IV of the Proclamation.

DATES:

Submission of information will be received on an ongoing basis starting September 23, 2026.

ADDRESSES:

Information requesting Commerce's approval for pharmaceutical products that meet an urgent U.S. health need must be submitted electronically to:
pharma232@bis.doc.gov.

FOR FURTHER INFORMATION CONTACT:

Stephen Astle, Director, Defense Industrial Base Division, Office of Strategic Industries and Economic Security, Bureau of Industry and Security, U.S. Department of Commerce (202) 482-2533,
pharma232@bis.doc.gov.

SUPPLEMENTARY INFORMATION:

I. Background

On April 2, 2026 the President issued Proclamation 11020, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,” (91 FR 18183) (Proclamation 11020) concurring with the Secretary of Commerce's (Secretary) finding that pharmaceuticals and associated pharmaceutical ingredients are being imported into the United States in such quantities and under such circumstances that threaten to impair the national security of the United States and imposing tariffs to adjust imports of such products pursuant to section 232 of the Trade Expansion Act of 1962, as amended (19 U.S.C. 1862) (Section 232). Proclamation 11020 imposed a 100 percent
ad valorem
tariff on certain imports of patented pharmaceuticals and associated pharmaceutical ingredients, effective July 31, 2026 for the companies listed in Annex III of Proclamation 11020, and September 29, 2026 for all other companies. Different rates apply to patented pharmaceutical products and associated ingredients from certain jurisdictions and from companies with Commerce-approved onshoring agreements (Bureau of Industry and Security, “Procedures To Apply for Company-Specific Onshoring Agreements To Obtain Tariff Adjustments for Pharmaceuticals and Pharmaceutical Ingredients Under Proclamation 11020” (92 FR 26989; May 13, 2026)). At this time, Section 232 Pharmaceutical Tariffs do not apply to generic pharmaceutical products and associated ingredients.

In clause 3(d) of Proclamation 11020, the President directed an
ad valorem
tariff rate of zero to apply for pharmaceuticals and associated ingredients that are designated as orphan pursuant to the Orphan Drug Act (21 U.S.C. 360aa
et seq.
) and its implementing regulations; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; or other specialty pharmaceutical products to be identified by the Secretary, as well as pharmaceutical products for animal health, provided that the Secretary, in consultation with the United States Trade Representative (USTR) and the Secretary of Health and Human Services (HHS), determines that: (1) they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement as referenced in Executive Order 14346, “Modifying the Scope of Reciprocal Tariffs and Establishing Procedures for Implementing Trade and Security Agreements” of September 5, 2025 (90 FR 43737) (Executive Order 14346), or (2) they meet an urgent U.S. health need.

Proclamation 11020 directs the Secretary, in consultation with the Chair of the United States International Trade Commission and the Commissioner of U.S. Customs and Border Protection (CBP), to determine whether any modifications to the HTSUS or other

administrative measures are necessary to effectuate or implement the Proclamation or any actions taken pursuant to the Proclamation. Any changes are to be published in a notice in the
Federal Register
.

II. Definitions of Pharmaceutical Products Listed in Clause 3(d) of Proclamation 11020

Commerce consulted with the Food and Drug Administration (FDA) and U.S. Department of Agriculture Center for Veterinary Biologics to provide the following definitions of the pharmaceutical products listed in clause 3(d) of Proclamation 11020. The definitions are solely for purposes of determining eligibility of the
ad valorem
tariff rate of zero pursuant to Proclamation 11020 and should not be construed as binding guidance for any other purpose unrelated to Proclamation 11020. This list of definitions covers imports of investigational drugs as well as FDA-approved or FDA-authorized drugs. Commerce reserves the right to modify these definitions in the future.

•
Drug where all approved or licensed indications are designated as orphan:
A drug or biological product that is designated under Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb) for one or more rare diseases or conditions, and for which all approved indications under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) of this title or licensed under Section 351 of the Public Health Service Act (42 U.S.C. 262), are for one or more such rare diseases or conditions.

•
Nuclear medicine:
A drug that meets the definition of “radioactive drug” in 21 CFR 310.3(n) or a biological product that meets the definition of “radioactive biological product” as defined in 21 CFR 600.3(ee).

○
21 CFR 301.3(n):
Radioactive drug means any substance defined as a drug in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act which exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons and includes any nonradioactive reagent kit or nuclide generator which is intended to be used in the preparation of any such substance but does not include drugs such as carbon-containing compounds or potassium-containing salts which contain trace quantities of naturally occurring radionuclides. The term `radioactive drug' includes a `radioactive biological product' as defined in 21 CFR 600.3(ee).

○
21 CFR 600.3(ee):
Radioactive biological product means a biological product which is labeled with a radionuclide or intended solely to be labeled with a radionuclide.

•
Plasma derived therapy:
A biological product that is derived from human whole blood or plasma. (42 U.S.C. 1320f-1(e)(3)(C)).

•
Fertility drug:
A drug or biological product for the treatment of infertility, including drugs approved for the treatment of ovulatory dysfunction in women desiring pregnancy.

•
Cell therapy product:
A biological product that is a cellular immunotherapy, cellular cancer vaccine, or other type of autologous or allogeneic cellular product approved for one or more therapeutic indications, including hematopoietic stem cell products and adult and embryonic stem cell products.

•
Gene therapy product:
A biological product that is intended to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use.

•
Antibody drug conjugates:
A combination product composed of a small-molecule drug (payload) and an antibody or antibody fragment, conjugated together by a chemical linker.

•
Medical countermeasures related to chemical, biological, radiological, and nuclear threats:
A drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)(1)), or a biological product as defined in section 351(i) of the Public Health Service Act (42 U.S.C. 262(i)), that is for use to diagnose, prevent, or treat diseases or conditions caused by chemical, biological, radiological, or nuclear threat (CBRN) agents, including emerging infectious diseases, and include qualified countermeasures as defined in section 319F-(a)(2)(A) of the Public Health Service Act (42 U.S.C. 247d-6a), qualified pandemic or epidemic products as defined in section 319F-3(i)(7) of the Public Health Service Act (42 U.S.C. 247d-6d); and security countermeasures as defined in section 319F-2(c)(1)(B) of the Public Health Service Act (42 U.S.C. 247d-6b).

•
Animal Healthcare Products:
Animal healthcare products include articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals; articles (other than food) intended to affect the structure or any function of an animal's body; or articles intended for use as components of such products. The definition includes veterinary pharmaceuticals intended to manage diseases, conditions, or injuries in animals but does not include devices or combination products for animals. Animal healthcare products also include biologics (vaccines, bacterins, and diagnostic products) used in the treatment of diseases in animals and is regulated by USDA-CVB (Center for Veterinary Biologics).

III. List of Eligible Jurisdictions

The following jurisdictions are eligible for the tariff adjustment described in clause 3(d) of Proclamation 11020: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, United Kingdom, and Vietnam. Changes to the list of eligible jurisdictions may be published in a future notice.

IV. Procedures for Requesting Commerce Approval for Pharmaceuticals That Meet an Urgent U.S. Health Need

Companies can request approval from Commerce for imports of pharmaceutical products listed in clause 3(d) of Proclamation 11020 or other specialty products if such imports meet an urgent U.S. health need. Companies should email the Bureau of Industry and Security (BIS) at
pharma232@bis.doc.gov
with the following information for each requested product or ingredient:

1.
Section 1—Organization Information:
Full legal name and address of the company. The name, title, and contact information of the authorized representative submitting the application should also be included.

2.
Section 2—Tariff Adjustment for Urgent U.
S.
Health Need:
Companies should provide the following information, with respect to the product for which they request preferential treatment to meet an urgent health need in the United States. Only one specific product may be submitted per application form.

• HTSUS Classification (10-digit, if possible)

• Advertised name and brand of product or Investigational New Drug Application number, as applicable, as well as active ingredient (or combination of active ingredients)

• Indicate the category of the requested product: orphan, nuclear medicine, plasma derived therapies, fertility drugs, cell therapy product, gene therapy product, antibody drug conjugates, medical countermeasures related to CBRN threats, or animal health

• Country of origin and country of export of products imported under each HTSUS Classification

• Name and IOR Number of Importer(s) of Record

• Name and address of manufacturer

3.
Section 3—Rationale for why the import meets an urgent U.S. health need:
The rationale can include information such as the type of disease the product treats and an assessment of alternative therapies or lack of alternative therapies for the type of disease the product treats, the number of U.S. patients that use the product, and whether or not the product is available in other jurisdictions. The requests for approval should only be for patented pharmaceutical products and associated ingredients that are covered under the HTSUS codes listed in Annex I of Proclamation 11020. Submission of information will be received on an ongoing basis.

Review and Approval Process

Commerce may request supplemental documentation or clarification. As directed in Proclamation 11020, Commerce will consult with the USTR and HHS to determine if the requested product meets an urgent U.S. health need. Commerce will make an individual, fact-specific, company-specific decision for each request. Companies will be notified in writing of Commerce's decision. Relevant information from the request will be transmitted by Commerce to CBP. CBP will administer the tariff adjustment at the time of entry summary filing and may request additional documentation to validate entries.

Confidentiality

Commerce will protect the confidentiality of all information submitted by companies requesting approval of specialty pharmaceutical product imports that meet an urgent U.S. health need.

Commerce will protect the confidentiality of confidential, trade secret, and/or proprietary information excluding information in the public domain (“confidential information”) provided by the Drug Manufacturer to the fullest extent allowed by law. For example, subject to applicable laws, such information would be protected from disclosure by the Trade Secrets Act (18 U.S.C. 1905) and under Exemptions 3 and/or 4 of the Freedom of Information Act (“FOIA”) (5 U.S.C. 552(b)(3), (4)). Commerce shall limit dissemination of a Drug Manufacturer's confidential information to those persons within its organization, USTR, and other executive branch agencies and entities who have a need to know such information to fulfill the purpose of determining whether imports of requested specialty pharmaceutical products meet an urgent U.S. health need.

V. Technical Corrections to the HTSUS

This notice and its accompanying annexes provide for five technical corrections to Annex I and one technical correction to Annex IV of Proclamation 11020.

Annex I Technical Corrections:
The first correction amends the definition of “generic pharmaceutical articles” in subdivision (c)(iii) with respect to heading 9903.04.67. The definition of “generic pharmaceutical articles” is modified to specifically include “unpatented animal health products.”

The second correction includes a new heading in Chapter 99 of the HTSUS with an ad valorem tariff rate of zero. Filers should use this new heading for pharmaceutical products and associated ingredients that are imported under HTSUS Classifications listed in subpart (c) of U.S. note 40 which are solely intended for clinical trials, research and development, or other non-commercial applications.

The third correction amends the definition of “pharmaceutical articles” in subdivision (c)(i) to clarify that this definition only encompasses finished pharmaceutical products, their active pharmaceutical ingredients, and the key starting materials of said active pharmaceutical ingredients.

The fourth correction amends the text of subdivision (i) with respect to heading 9903.04.69 to clarify that this provision encompasses any pharmaceutical or non-pharmaceutical articles imported under an HTSUS Classification listed in subpart (c) of U.S. note 40 that are not finished pharmaceutical products, their active pharmaceutical ingredients, or the key starting materials of said active pharmaceutical ingredients.

The fifth correction amends Annex I to incorporate recent HTSUS changes made by the Committee for the Statistical Annotation of Tariff Schedules on July 1, 2026. This interagency committee includes representatives from the U.S. International Trade Commission, CBP, and the U.S. Census Bureau.

Annex IV Technical Correction:
The technical correction to Annex IV corrects an inconsistency of certain HTSUS Classifications listed in Annex IV that overlap with Annex I. The following HTSUS codes are removed from Annex IV: 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00, and 3004.49.00.

VI. Paperwork Reduction Act

The Paperwork Reduction Act of 1995 (44 U.S.C. 3501
et seq.
) provides that an agency generally cannot conduct or sponsor a collection of information, and no person is required to respond to nor be subject to a penalty for failure to comply with a collection of information, unless that collection has obtained Office of Management and Budget (OMB) approval and displays a currently valid OMB Control Number.

In Proclamation 11020, the President determined it was necessary and appropriate to apply an
ad valorem
tariff rate of zero for the following specialty pharmaceutical products and associated ingredients when certain conditions are met pursuant to clause 3(d) of Proclamation 11020: drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; and animal health. The President authorized the Secretary of Commerce, in consultation with the USTR and the Secretary of HHS, to determine that: (1) they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement as referenced in Executive Order 14346; or (2) they meet an urgent United States health need.

Because the Proclamation requires timely implementation of the specialty pharmaceutical tariff adjustments to further U.S. economic and national security interests by making pharmaceuticals more accessible and affordable in the United States, BIS cannot reasonably comply with the normal clearance procedures. Delaying this collection would impede the ability of companies to request approval for imports of specialty pharmaceutical products that meet an urgent United States health need and compromise the effectiveness of the Proclamation's implementation. The Department has determined the following conditions have been met:

a. The collection of information is needed prior to the expiration of time periods normally associated with a routine submission for review under the provisions of the Paperwork Reduction Act in view of Proclamation 11020,
https://www.federalregister.gov/documents/2026/04/09/2026-06956/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states.
(5 CFR 1320.13(a)(1)(i)).

b. The collection of information is essential to the mission of the Department, in particular to allow companies seeking to obtain the zero
ad valorem
tariff by requesting approval for imports of specialty pharmaceutical products that meet an urgent United States health need to effectuate the terms outlined by Proclamation 11020 (5 CFR 1320.13(a)(1)(ii)). These collection requirements include a description of the specialty pharmaceutical product, country of origin information, and rationale for why the import meets an urgent United States health need. The information must be submitted in electronic form via email to the BIS Section 232 Pharmaceuticals Investigation Inbox (
pharma232@bis.doc.gov
). Requests for approval of imports that meet an urgent United States health need may be submitted at any time following publication of this FRN publication and all submissions are entirely voluntary on the part of the requesting companies.

c. Public harm is reasonably likely to result if BIS were to follow the normal clearance procedures before issuing this information collection (5 CFR 1320.13(a)(2)(i)). BIS needs time to receive and evaluate requests for specialty pharmaceutical products that meet an urgent United States health need before September 29, 2026, when the Section 232 tariffs for most companies will become effective. A delay in Commerce's ability to begin immediate information collection from companies seeking approval to import specialty pharmaceutical products that meet an urgent United States health need and inability to issue decisions before the 100 percent tariff rate is in effect creates uncertainty for companies' understanding of their tariff liability and could also cause supply chain disruptions.

For the reasons stated above, BIS has requested, and OMB has granted, a new information collection for this rule under OMB control number 0694-0150 with the title
Section 232 National Security Adjustments to Imports of Specialty Pharmaceuticals.
All materials for the currently approved collection can be accessed at
www.reginfo.gov.
Separately, BIS will be publishing a 60 day notice to take comment on the emergency collection.

Jessica Curyto,
Deputy Assistant Secretary for Technology Security.

Annex I

Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on September 29, 2026, subchapter III of chapter 99 of the Harmonized Tariff Schedule of the United States (“HTSUS”) is modified as follows:

1. U.S. note 40 is modified:

a. In subdivision (a), by deleting “9903.04.60-9903.04.69” and inserting “9903.04.60-9903.04.70” in lieu thereof;

b. In subdivision (c), by deleting the enumerated HTSUS provisions and inserting the following in lieu thereof:

“2918.99.3000
2921.49.3800
2921.49.4300
2922.19.0910

2922.19.0990
2922.29.2700
2922.49.2600
2922.50.1400

2922.50.2500
2924.29.6250
2925.29.2000
2928.00.3000

2930.90.9235
2931.90.2200
2932.20.2000
2933.19.3500

2933.19.4500
2933.29.2000
2933.29.4500
2933.39.4100

2933.49.2600
2933.59.2100
2933.59.3600
2933.59.4600

2933.59.5300
2933.59.5900
2933.79.0800
2933.79.8500

2933.99.4600
2933.99.5300
2933.99.5590
2933.99.6100

2933.99.6500
2933.99.7000
2933.99.7500
2933.99.9000

2934.30.2300
2934.30.2700
2934.99.3000
2934.99.4720

2934.99.4730
2934.99.4740
2934.99.4790
2935.90.4800

2935.90.6000
2937.11.0000
2937.12.0000
2937.19.0000

2937.22.0010
2937.22.0090
2937.23.1010
2937.23.1050

2937.23.5010
2937.23.5020
2937.23.5050
2937.29.9040

2937.29.9050
2937.29.9095
2937.50.0000
2937.90.4500

2937.90.9000
2938.90.0000
2939.11.0000
2939.19.2000

2939.19.5000
2941.10.5000
2941.90.1050
2941.90.3030

2941.90.3090
2941.90.5030
2941.90.5090
2942.00.0500

3002.12.0040
3002.13.0010
3002.13.0090
3002.14.0010

3002.14.0090
3002.15.0011
3002.15.0091
3002.41.0000

3002.42.0000
3002.49.0050
3002.51.0000
3002.59.0000

3002.90.1000
3002.90.5220
3002.90.5250
3003.20.0000

3003.31.0000
3003.39.1000
3003.39.5000
3003.49.0000

3003.90.0120
3003.90.0140
3003.90.0180
3003.90.0190

3004.10.1010
3004.10.5010
3004.20.0010
3004.20.0042

3004.20.0058
3004.20.0073
3004.20.0074
3004.20.0078

3004.20.0085
3004.31.0010
3004.31.0090
3004.32.0020

3004.32.0080
3004.39.0010
3004.39.0015
3004.39.0080

3004.41.0000
3004.49.0005
3004.49.0010
3004.49.0020

3004.49.0030
3004.49.0040
3004.49.0050
3004.49.0060

3004.49.0070
3004.50.5005
3004.90.1000
3004.90.9201

3004.90.9206
3004.90.9208
3004.90.9210
3004.90.9211

3004.90.9212
3004.90.9215
3004.90.9216
3004.90.9217

3004.90.9218
3004.90.9226
3004.90.9236
3004.90.9243

3004.90.9246
3004.90.9249
3004.90.9251
3004.90.9252

3004.90.9253
3004.90.9260
3004.90.9263
3004.90.9267

3004.90.9268
3004.90.9270
3004.90.9271
3004.90.9273

3004.90.9276”

c. In subdivision (c), by deleting item (i) and inserting the following in lieu thereof:

“(i) “Pharmaceutical articles” refers to imported articles classifiable in the provisions enumerated in this subdivision that are finished pharmaceutical products or that are active pharmaceutical ingredients (including key starting materials for active pharmaceutical ingredients) classifiable in the provisions enumerated in this subdivision used to make finished pharmaceutical products. Inactive ingredients and excipients are not pharmaceutical articles.”;

d. In subdivision (c)(iii), by deleting the second sentence and inserting the following sentence in lieu thereof:

“A generic pharmaceutical article is an active pharmaceutical ingredient or any component in a finished dosage form product that is used in a drug product or biosimilar biological product approved pursuant to a qualifying application; or a drug product or biosimilar biological product approved or licensed pursuant to a qualifying application; or an unpatented animal health product.”; and

e. By deleting subdivision (i) and inserting the following in lieu thereof:

“(i) Heading 9903.04.69 applies to entries of articles that are classifiable under provisions of the HTSUS enumerated in subdivision (c) of this note that are either: (1) not “pharmaceutical articles” as defined in subdivision (c)(i) of this note, or (2) are “pharmaceutical articles” but are neither “patented pharmaceutical articles” nor “generic pharmaceutical articles” as those terms are defined in subdivisions (c)(ii) and (c)(iii) of this note.”

2. The following new heading is inserted in numerical sequence, with the material for the new heading inserted in the columns of the HTSUS labeled “Heading/Subheading”, “Article Description”, “Rates of Duty 1-General”, “Rates of Duty 1-Special” and “Rates of Duty 2”, respectively:

Heading/
subheading

Article description
Rates of duty
1
General
Special
2

“9903.04.70
Pharmaceutical articles and associated ingredients provided for in subdivision (c) of U.S. note 40 to this subchapter that are solely for use in clinical trials, research and development, or other non-commercial applications
The duty provided in the applicable subheading + 0%
The duty provided in the applicable subheading + 0%
The duty provided in the applicable subheading + 0%”.

Annex II

Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on September 29, 2026, Annex IV of Presidential Proclamation 11020 of April 2, 2026, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,” (Proclamation 11020) is modified by deleting the enumerated HTSUS provisions and inserting the following in lieu thereof:

“2903.45.1000
2903.51.1000
2903.59.9000
2903.69.9000

2903.78.0000
2903.79.9030
2903.79.9070
2903.89.1500

2903.89.2000
2903.89.7010
2903.89.7090
2903.92.0000

2904.99.4000
2905.29.9000
2905.39.9000
2905.59.1000

2905.59.9000
2906.19.5000
2906.29.6000
2907.29.9000

2908.19.6000
2909.19.1800
2909.20.0000
2909.30.6000

2909.49.1000
2909.49.1500
2909.49.2000
2909.49.6000

2909.50.4010
2909.50.4050
2909.50.4500
2909.50.5000

2912.19.5000
2912.49.2600
2914.19.0000
2914.40.9000

2914.50.3000
2914.50.5000
2914.62.0000
2914.69.2100

2914.69.9000
2914.79.4000
2915.29.3000
2915.39.3100

2915.39.3500
2915.39.4700
2915.39.9000
2915.90.1010

2915.90.1050
2915.90.1400
2915.90.1810
2915.90.1890

2915.90.2000
2915.90.5010
2915.90.5050
2916.19.3000

2916.19.5000
2916.20.5000
2916.31.5000
2916.39.4600

2916.39.7900
2917.13.0030
2917.13.0090
2917.19.1000

2917.19.7020
2917.19.7050
2917.34.0110
2917.34.0150

2917.39.3000
2918.11.5100
2918.13.5000
2918.16.5010

2918.16.5020
2918.16.5090
2918.19.6000
2918.19.9000

2918.22.1000
2918.22.5000
2918.23.3000
2918.23.5000

2918.29.2000
2918.29.6500
2918.29.7500
2918.30.2500

2918.30.3000
2918.30.9000
2918.99.4300
2918.99.4700

2918.99.5000
2919.90.3000
2919.90.5010
2919.90.5050

2920.90.5100
2921.19.1100
2921.29.0010
2921.29.0020

2921.29.0030
2921.29.0055
2921.30.1000
2921.30.5000

2921.42.9000
2921.46.0000
2921.49.4500
2921.49.5000

2921.59.8010
2921.59.8090
2922.11.0000
2922.14.0000

2922.19.2000
2922.19.3300
2922.19.6000
2922.19.7000

2922.19.9000
2922.19.9610
2922.19.9619
2922.19.9690

2922.29.6100
2922.29.8110
2922.29.8190
2922.31.0000

2922.39.2500
2922.39.4500
2922.39.5000
2922.41.0010

2922.41.0090
2922.42.5000
2922.44.0000
2922.49.1000

2922.49.3000
2922.49.3700
2922.49.4910
2922.49.4915

2922.49.4950
2922.49.8000
2922.50.0700
2922.50.1000

2922.50.1100
2922.50.1300
2922.50.1700
2922.50.3500

2922.50.4000
2922.50.5000
2923.10.0000
2923.20.2010

2923.20.2050
2924.11.0000
2924.19.1110
2924.19.1120

2924.19.1130
2924.19.1150
2924.19.8000
2924.21.1600

2924.21.5000
2924.29.0100
2924.29.0300
2924.29.1000

2924.29.2300
2924.29.2600
2924.29.2800
2924.29.3300

2924.29.5700
2924.29.6210
2924.29.6220
2924.29.7100

2924.29.7710
2924.29.7720
2924.29.7730
2924.29.7790

2924.29.8000
2924.29.9500
2925.12.0000
2925.19.4200

2925.19.9100
2925.21.0000
2925.29.6000
2925.29.9000

2926.30.1000
2926.40.0000
2926.90.1400
2926.90.4300

2926.90.4801
2926.90.5010
2926.90.5050
2927.00.4000

2927.00.5000
2928.00.2500
2929.90.2000
2929.90.5015

2929.90.5018
2929.90.5020
2929.90.5030
2929.90.5040

2929.90.5095
2930.20.2010
2930.20.2050
2930.20.9010

2930.20.9020
2930.20.9050
2930.30.6000
2930.90.2900

2930.90.4910
2930.90.4920
2930.90.4950
2930.90.9208

2930.90.9210
2930.90.9212
2930.90.9222
2930.90.9225

2930.90.9231
2930.90.9251
2931.49.0005
2931.49.0008

2931.49.0010
2931.49.0015
2931.49.0020
2931.49.0025

2931.49.0055
2931.49.0080
2931.53.0000
2931.90.9010

2931.90.9021
2931.90.9025
2931.90.9029
2931.90.9030

2931.90.9035
2931.90.9040
2931.90.9052
2932.14.0000

2932.19.5100
2932.20.3000
2932.20.5010
2932.20.5020

2932.20.5030
2932.20.5050
2932.99.6100
2932.99.7000

2932.99.9010
2932.99.9090
2933.11.0000
2933.19.9000

2933.21.0000
2933.29.0500
2933.29.3500
2933.29.4300

2933.29.6000
2933.29.9000
2933.33.0100
2933.34.0000

2933.35.0000
2933.37.0000
2933.39.0800
2933.39.1000

2933.39.2000
2933.39.2100
2933.39.2300
2933.39.2500

2933.39.2700
2933.39.3100
2933.39.6110
2933.39.6120

2933.39.6130
2933.39.6191
2933.39.9200
2933.41.0000

2933.49.0800
2933.49.1000
2933.49.1500
2933.49.1700

2933.49.2000
2933.49.3000
2933.49.6000
2933.49.7000

2933.52.1000
2933.52.9000
2933.53.0000
2933.54.0000

2933.59.1000
2933.59.1500
2933.59.1800
2933.59.2200

2933.59.7000
2933.59.8000
2933.59.8500
2933.59.9500

2933.69.6010
2933.69.6021
2933.69.6030
2933.69.6050

2933.72.0000
2933.79.1500
2933.91.0010
2933.91.0050

2933.99.0100
2933.99.0200
2933.99.0500
2933.99.0600

2933.99.0800
2933.99.1100
2933.99.1200
2933.99.1600

2933.99.1701
2933.99.2200
2933.99.2400
2933.99.2600

2933.99.4200
2933.99.5100
2933.99.5510
2933.99.5520

2933.99.5530
2933.99.5800
2933.99.7900
2933.99.8210

2933.99.8220
2933.99.8290
2933.99.8500
2933.99.8900

2933.99.9701
2934.10.1000
2934.10.2000
2934.10.9000

2934.20.4000
2934.20.8000
2934.30.4300
2934.30.5000

2934.91.0000
2934.92.0000
2934.99.0100
2934.99.0300

2934.99.0500
2934.99.0600
2934.99.0700
2934.99.0800

2934.99.0900
2934.99.1100
2934.99.1200
2934.99.1500

2934.99.1600
2934.99.1800
2934.99.2000
2934.99.3900

2934.99.4400
2934.99.7000
2934.99.9001
2935.50.0000

2935.90.0600
2935.90.1000
2935.90.1300
2935.90.1500

2935.90.2000
2935.90.3000
2935.90.3200
2935.90.3300

2935.90.4200
2935.90.7500
2935.90.9500
2936.21.0000

2936.22.0000
2936.23.0000
2936.24.0100
2936.25.0000

2936.26.0000
2936.27.0000
2936.28.0000
2936.29.1000

2936.29.1610
2936.29.1620
2936.29.1630
2936.29.2000

2936.29.5020
2936.29.5030
2936.29.5050
2936.90.0110

2936.90.0150
2937.21.0010
2937.21.0020
2937.21.0030

2937.21.0040
2937.23.1020
2937.23.2500
2937.29.1000

2937.29.9020
2937.29.9030
2937.90.0500
2937.90.1000

2937.90.2000
2937.90.4000
2938.10.0000
2939.19.1000

2939.20.0010
2939.20.0050
2939.30.0000
2939.41.0000

2939.42.0000
2939.44.0000
2939.45.0000
2939.49.0300

2939.59.0000
2939.62.0000
2939.63.0000
2939.69.0000

2939.72.0000
2939.79.0000
2939.80.0010
2939.80.0050

2940.00.6000
2941.10.1000
2941.10.2000
2941.10.3000

2941.20.1000
2941.20.5000
2941.30.0000
2941.40.0000

2941.50.0000
2941.90.1010
2942.00.3500
2942.00.5000

3001.20.0000
3001.90.0110
3001.90.0150
3001.90.0165

3001.90.0195
3002.12.0010
3002.12.0020
3002.12.0030

3002.12.0090
3002.49.0010
3002.90.5210
3003.10.0000

3003.41.0000
3003.42.0000
3003.90.0160
3004.10.1020

3004.10.1045
3004.10.5048
3004.10.5049
3004.10.5055

3004.10.5065
3004.10.5075
3004.20.0020
3004.20.0030

3004.20.0045
3004.20.0055
3004.20.0065
3004.20.0070

3004.20.0071
3004.20.0072
3004.20.0076
3004.20.0080

3004.32.0010
3004.32.0040
3004.39.0020
3004.39.0030

3004.39.0040
3004.39.0045
3004.42.0000
3004.50.1000

3004.50.2000
3004.50.3000
3004.50.4000
3004.50.5010

3004.50.5020
3004.50.5030
3004.50.5040
3004.60.0000

3004.90.9203
3004.90.9204
3004.90.9205
3004.90.9207

3004.90.9209
3004.90.9212
3004.90.9213
3004.90.9217

3004.90.9218
3004.90.9219
3004.90.9220
3004.90.9222

3004.90.9223
3004.90.9224
3004.90.9226
3004.90.9227

3004.90.9228
3004.90.9229
3004.90.9230
3004.90.9232

3004.90.9233
3004.90.9234
3004.90.9235
3004.90.9237

3004.90.9238
3004.90.9239
3004.90.9240
3004.90.9241

3004.90.9242
3004.90.9244
3004.90.9245
3004.90.9247

3004.90.9248
3004.90.9250
3004.90.9254
3004.90.9255

3004.90.9256
3004.90.9257
3004.90.9258
3004.90.9261

3004.90.9262
3004.90.9264
3004.90.9265
3004.90.9266

3004.90.9269
3004.90.9272
3004.90.9274
3004.90.9275

3006.30.1000
3006.30.5000
3006.60.0000
3006.70.0000

3006.93.1000
3006.93.2000
3006.93.5000
3006.93.6000

3006.93.8000”

[FR Doc. 2026-19498 Filed 9-21-26; 4:15 pm]
BILLING CODE 3510-33-P

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/fr%3A2026-19498. Public record. Not legal advice.